Abstract A094: Mapping early Pancreatic Cancer evolution through enhancer reprogramming and transcription factor interactomes
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies, with poor survival largely driven by late-stage diagnosis. Approximately 85% of patients present with advanced disease, limiting curative treatment options. A major challenge in PDAC is the absence of biomarkers capable of identify...